The single pill would focus on all three major blood lipids LDL-C bad cholesterol.

AstraZeneca and Abbott confirm Phase III clinical trials of Fenofibrate ABT-335 and Crestor as fixed-dose combination Abbott and AstraZeneca confirmed they’ll advance the development of Abbott’s next-era fenofibrate ABT-335 and AstraZeneca’s CRESTOR in a fixed-dose combination treatment into Stage III clinical trials www.tretinoincream.org . The single pill would focus on all three major blood lipids – – LDL-C ‘bad’ cholesterol, HDL-C ‘great’ cholesterol, and triglycerides. ABT-335 can be Abbott’s next-generation fenofibrate presently in late-stage scientific trials. Predicated on the significant progress made in the ABT-335 and CRESTOR fixed-dose mixture development program, the companies have decided to move forward with this fixed-dosage combination therapy jointly.